Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Dr. Ethan Craig Picks His Favorite Gout Abstracts from ACR Convergence 2020

  |  Issue: January 2021  |  

[Back to the Resource Center.]

Keri Losavio is the staff editor of The Rheumatologist.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018 Mar 29;378(13):1200–1210.
  2. MacDonald T, Mackenzie I, Nuki G, Ford I. Long term cardiovascular safety of febuxostat and allopurinol in patients with chronic gout: The febuxostat versus allopurinol streamlined trial (on Behalf of the FAST Investigators) [abstract]. Arthritis Rheumatol. 2020 Oct;72(suppl 10).

Related Articles